Cargando…
Designed CXCR4 mimic acts as a soluble chemokine receptor that blocks atherogenic inflammation by agonist-specific targeting
Targeting a specific chemokine/receptor axis in atherosclerosis remains challenging. Soluble receptor-based strategies are not established for chemokine receptors due to their discontinuous architecture. Macrophage migration-inhibitory factor (MIF) is an atypical chemokine that promotes atherosclero...
Autores principales: | Kontos, Christos, El Bounkari, Omar, Krammer, Christine, Sinitski, Dzmitry, Hille, Kathleen, Zan, Chunfang, Yan, Guangyao, Wang, Sijia, Gao, Ying, Brandhofer, Markus, Megens, Remco T. A., Hoffmann, Adrian, Pauli, Jessica, Asare, Yaw, Gerra, Simona, Bourilhon, Priscila, Leng, Lin, Eckstein, Hans-Henning, Kempf, Wolfgang E., Pelisek, Jaroslav, Gokce, Ozgun, Maegdefessel, Lars, Bucala, Richard, Dichgans, Martin, Weber, Christian, Kapurniotu, Aphrodite, Bernhagen, Jürgen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689490/ https://www.ncbi.nlm.nih.gov/pubmed/33239628 http://dx.doi.org/10.1038/s41467-020-19764-z |
Ejemplares similares
-
A MIF‐Derived Cyclopeptide that Inhibits MIF Binding and Atherogenic Signaling via the Chemokine Receptor CXCR2
por: Krammer, Christine, et al.
Publicado: (2020) -
Identification of an Arg-Leu-Arg tripeptide that contributes to the binding interface between the cytokine MIF and the chemokine receptor CXCR4
por: Lacy, Michael, et al.
Publicado: (2018) -
The Multitasking Potential of Alarmins and Atypical Chemokines
por: Kapurniotu, Aphrodite, et al.
Publicado: (2019) -
Heterocomplexes between the atypical chemokine MIF and the CXC-motif chemokine CXCL4L1 regulate inflammation and thrombus formation
por: Brandhofer, Markus, et al.
Publicado: (2022) -
Designed peptides as nanomolar cross-amyloid inhibitors acting via supramolecular nanofiber co-assembly
por: Taş, Karin, et al.
Publicado: (2022)